Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 5, 2014, Pages 637-644

  Apolo, Andrea B ^a   Kim, Joseph W ^b   Bochner, Bernard H ^c   Steinberg, Seth M ^a   Bajorin, Dean F ^c   Kevin Kelly, Wm ^d   Agarwal, Piyush K ^a   Koppie, Theresa M ^e   Kaag, Matthew G ^f   Quinn, David I ^g   Vogelzang, Nicholas J ^h,i   Sridhar, Srikala S ^j  

^a NATIONAL CANCER INSTITUTE   (United States)

^b YALE CANCER CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

ⁱ Department of Hematology Oncology   (United States)

^j PRINCESS MARGARET HOSPITAL   (Canada)

more..

Author keywords

Adjuvant chemotherapy; Medical oncologist; Muscle invasive bladder cancer; Neoadjuvant chemotherapy; Survey

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CYSTECTOMY; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; GLOMERULUS FILTRATION RATE; HEALTH CARE SURVEY; HUMAN; LYMPH VESSEL METASTASIS; MEDICAL ONCOLOGIST; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NORMAL HUMAN; PATIENT REFERRAL; PRIORITY JOURNAL; STANDARDIZATION; TRANSITIONAL CELL CARCINOMA; UNITED STATES; UROLOGIST; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; MIDDLE AGED; MUSCLE; ONCOLOGY; PATHOLOGY; QUESTIONNAIRE; TUMOR INVASION; URINARY BLADDER NEOPLASMS; UROLOGY; UTILIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; MUSCLES; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; QUESTIONNAIRES; UNITED STATES; URINARY BLADDER NEOPLASMS; UROLOGY;

EID: 84902551364     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.12.012     Document Type: Article

References (27)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Kirkali Z., Chan T., Manoharan M., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005, 66:4-34.
3. Skinner D.G., Lieskovsky G. Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 1984, 131:1069-1072.
4. Herr H.W., Dotan Z., Donat S.M., Bajorin D.F. Defining optimal therapy for muscle invasive bladder cancer. J Urol 2007, 177:437-443.
5. International Collaboration of T, Medical Research Council Advanced Bladder Cancer Working P, European Organisation for R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011, 29:2171-2177.
6. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349:859-866.
7. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005, 48:202-205. [discussion 205-206].
8. David K.A., Milowsky M.I., Ritchey J., et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 2007, 178:451-454.
9. Schrag D., Mitra N., Xu F., et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology 2005, 65:1118-1125.
10. Porter M.P., Kerrigan M.C., Donato B.M.K., Ramsey S.D. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol 2011, 29:252-258.
11. Feifer A., Taylor J.M., Shouery M., Steinberg G.D., Stadler W.M., Schoenberg M., et al. Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: phase I. J Clin Oncol 2011, 29. [suppl 7, abstr 240].
12. Fedeli U., Fedewa S.A., Ward E.M. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol 2011, 185:72-78.
13. Dash A., Galsky M.D., Vickers A.J., et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006, 107:506-513.
14. Hussain S.A., Stocken D.D., Riley P., et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 2004, 91:844-849.
15. Bellmunt J., Ribas A., Eres N., et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997, 80:1966-1972.
16. Petrioli R., Frediani B., Manganelli A., et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996, 77:344-351.
17. Dogliotti L., Carteni G., Siena S., et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007, 52:134-141.
18. Galsky M.D., Chen G.J., Oh W.K., et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 2012, 23:406-410.
19. deVere White R.W., Lara P.N., Goldman B., et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol 2009, 181:2476-2480. [discussion 2480-2471].
20. Sternberg C.N., de Mulder P.H., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001, 19:2638-2646.
21. Sternberg C.N., de Mulder P., Schornagel J.H., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006, 42:50-54.
22. Apolo A.B., Grossman H.B., Bajorin D., et al. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol 2012, 30:772-780.
23. Splinter T.A., Scher H.I., Denis L., et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer-Genitourinary Group. J Urol 1992, 147:606-608.
24. Schultz P.K., Herr H.W., Zhang Z.F., et al. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 1994, 12:1394-1401.
25. Millikan R., Dinney C., Swanson D., et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001, 19:4005-4013.
26. + disease after preoperative chemotherapy and radical cystectomy. Urology 2009, 73:147-152.
27. Apolo A.B., Riches J., Schoder H., et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 2010, 28:3973-3978.